Amaza Reitmeier, vice president and general manager for Medtronic Brain Modulation, said: “This development represents a critical step in our journey to transform Brain Modulation through sensing-enabled DBS. We are excited about the potential of Percept RC to provide a comfortable, personalised DBS therapy to those living with Parkinson’s Disease, Essential Tremor and Primary Dystonia. Percept RC is also the only rechargeable neurostimulator approved to serve patients with Epilepsy.”
Domenico De Paolis, vice president Neuromodulation International, which is part of the Neuroscience Portfolio at Medtronic, added: “In addition to being the smallest DBS device on the market, Percept RC combines proprietary battery technology with our brain-sensing technology. These innovations are the culmination of 30 years of investment in clinical trials and R&D to improve the experience of DBS patients.”
Overdrive battery technology allows physicians to adjust therapy without impacting battery capacity. With weekly charging, the device has greater than 99% battery capacity at 15 years. Rapid recharging means that patients can charge under normal conditions (from 10% to 90% full) in less than an hour.